More French drug price cuts in store as 'stability programme' gets green light
This article was originally published in SRA
Executive Summary
The French pharmaceutical industry is again under the hammer. Parliament has passed a package of measures including proposals to slice €10bn of healthcare spending over the 2015-17 period – some €3.5bn of which will affect medicines, and probably medical devices – in the form of selected price cuts, together with moves to increase the market share of generics.
You may also be interested in...
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.